Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF

Lancet. 1990 Feb 24;335(8687):434-7. doi: 10.1016/0140-6736(90)90665-r.

Abstract

In 4 out of 16 patients receiving recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) in phase I/II studies antibodies developed to the recombinant protein. The antibodies react with sites on the native protein backbone which are normally protected by O-linked glycosylation but which are exposed in rhGM-CSF produced in yeast and Escherichia coli. Antigenicity of recombinant human proteins due to non glycosylation may have relevance to the choice of host system for production of factors for clinical use.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies / analysis*
  • Antibody Formation
  • Antibody Specificity / immunology
  • Binding Sites, Antibody / immunology*
  • Blotting, Western / methods
  • Bone Marrow Examination / methods
  • Clinical Trials as Topic
  • Colony-Stimulating Factors / administration & dosage
  • Colony-Stimulating Factors / blood
  • Colony-Stimulating Factors / immunology*
  • Colony-Stimulating Factors / therapeutic use
  • Drug Administration Schedule
  • Enzyme-Linked Immunosorbent Assay / methods
  • Escherichia coli
  • Glycosylation
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Growth Substances / administration & dosage
  • Growth Substances / blood
  • Growth Substances / immunology*
  • Growth Substances / therapeutic use
  • Humans
  • Immunoglobulin G / analysis*
  • Infusions, Intravenous
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / blood
  • Recombinant Proteins / immunology
  • Recombinant Proteins / therapeutic use
  • Time Factors
  • Yeasts

Substances

  • Antibodies
  • Colony-Stimulating Factors
  • Growth Substances
  • Immunoglobulin G
  • Recombinant Proteins
  • Granulocyte-Macrophage Colony-Stimulating Factor